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Mesenchymal stem cells are a promising source for externally grown tissue
replacements and patient-specific immunomodulatory treatments. This promise has not
yet been fulfilled in part due to production scaling issues and the need to maintain
the correct phenotype after re-implantation. One aspect of extracorporeal growth
that may be manipulated to optimize cell growth and differentiation is metabolism.
The metabolism of MSCs changes during and in response to differentiation and
immunomodulatory changes. MSC metabolism may be linked to functional differences
but how this occurs and influences MSC function remains unclear. Understanding how
MSC metabolism relates to cell function is however important as metabolite availability
and environmental circumstances in the body may affect the success of implantation.
Genome-scale constraint based metabolic modeling can be used as a tool to fill gaps
in knowledge of MSC metabolism, acting as a framework to integrate and understand
various data types (e.g., genomic, transcriptomic and metabolomic). These approaches
have long been used to optimize the growth and productivity of bacterial production
systems and are being increasingly used to provide insights into human health research.
Production of tissue for implantation using MSCs requires both optimized production
of cell mass and the understanding of the patient and phenotype specific metabolic
situation. This review considers the current knowledge of MSC metabolism and how it
may be optimized along with the current and future uses of genome scale constraint
based metabolic modeling to further this aim.
Keywords: MSCs, metabolism, personalized/precision medicine, metabolomics, metabolic modeling, tissue
engineering
INTRODUCTION
In recent years, there has been increasing interest in the possibilities offered by regenerative
medicine (Maienschein, 2011; Sampogna et al., 2015), a field which seeks solutions for the
restoration of the structure and functions of organs and tissues that have become permanently
damaged. While regenerative medicine has enjoyed success in some areas, treatment can result in
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danger to patients or in therapeutic inefficiency (Neman et al.,
2012; Campana et al., 2014; Goldberg et al., 2017; Moreira et al.,
2017; Cunningham et al., 2018; Solarte et al., 2018) that have
pushed researchers to continuously search for novel approaches
to address limitations.
One important area of regenerative medicine is the use of
stem cells to enhance available therapeutic applications and
to further the development of new ones (Mahla, 2016). In
particular, mesenchymal stem cells, or mesenchymal stromal
cells (MSCs) (Rosenbaum et al., 2008; Ullah et al., 2015;
Fitzsimmons et al., 2018), are of interest. MSCs are multipotent
cell types with stem cell-like abilities that can be isolated from
various adult and neonatal tissues (Nombela-Arrieta et al.,
2011; Alberts et al., 2014). MSCs maintain proliferation abilities
while possessing the ability to undergo trilineage differentiation
(adipogenic, chondrogenic, and osteogenic differentiation) and
remarkable immunomodulatory capabilities (Rosenbaum et al.,
2008; Lin et al., 2013). These properties offer the possibility
of furthering treatment options for various ailments, such
as metabolic and autoimmune diseases like multiple sclerosis
(Bonab et al., 2012), Alzheimer’s disease (Rosenbaum et al., 2008;
Mahla, 2016), diabetes (Ullah et al., 2015; Fitzsimmons et al.,
2018), Crohn’s disease (Duijvestein et al., 2010), and cancer
(Qin et al., 2016).
For the past decade, MSCs metabolism has received
growing interest due to mounting evidence suggesting that the
manipulation of metabolism allows enhanced therapeutic uses of
these cells (e.g., cell retention, cell survival, immunoregulation,
differentiation) in cell-based medicine and tissue engineering
(Chen et al., 2008; Croitoru-Lamoury et al., 2011; Pattappa
et al., 2011; Buravkova et al., 2013; Beegle et al., 2015; Shum
et al., 2016; Li et al., 2017; Meyer et al., 2018; Vigo et al.,
2019; Zhu and Thompson, 2019). Cellular metabolism is an
intricate and complex network of pathways, enzymatic reactions,
metabolites, and co-factors with numerous effects on the cell
and its immediate surroundings. Due to the complexity of
metabolism and its effects, research into the possibilities of
manipulating metabolism in these cells has been slow.
The advent of high-throughput -omic technologies (Henry
et al., 2010; Resendis-Antonio, 2013) has allowed for the detailing
of genome-scale metabolic networks (Yurkovich and Palsson,
2016). This holistic systems biology approach acknowledges
that biological systems are made up of a network of networks
(Reed and Palsson, 2003; Resendis-Antonio, 2013; Bordbar et al.,
2014). Genome-scale models (GEMs) of metabolism (Rocha
et al., 2008) provide a framework for the computation of the
genotype-phenotype relationship in which various types of -
omics data can be integrated along with organism-specific
network reconstructions to generate tissue, cell, or organism
specific in silico models (Feist et al., 2009; Chang et al., 2010;
Agren et al., 2014; Fouladiha et al., 2015). These models
can then be constrained by experimental measurements and
computed in order to explore possible therapeutic applications,
making use of the newest RNA sequencing and metabolomic
data or in vitro experimentation. Such models will aid further
understanding of MSCs metabolism under various external
or internal conditions. Thus far, metabolic modeling has not
been applied to the study of MSCs, but this area offers
great possibilities for enhancing both research and therapeutic
application of these cells.
In this review, we describe how the study of human MSC
(hMSC) metabolism can be used to answer the fundamental
question: “How can GEMs be used to optimize MSC
therapeutics?” First, we describe the biology of MSCs, their
differentiation and immunomodulation properties and their
applications and limitations in regenerative medicine. Next,
we detail how metabolism affects or can be used to manipulate
these functions. We then discuss how mathematical modeling
of hMSC metabolism can aid in developing pre-clinical and
clinical experiments. Finally, we give our vision for the future
of using metabolic modeling to study hMSCs and how the
resulting insights could prove transformative for the field of
regenerative medicine.
BIOLOGY OF MESENCHYMAL STEM
CELLS (MSCs)
Mesenchymal stromal cells comprise non-hematopoietic cells
originating from the mesodermal germ layer and are capable of
both self-renewal and multilineage differentiation into various
tissues of mesodermal origin (Gazit et al., 2014). These
multipotent cells can be isolated both from various adult
tissues (e.g., skin, peripheral blood, bone marrow) and neonatal
tissues (e.g., Wharton’s jelly, umbilical cord blood) (Nombela-
Arrieta et al., 2011; Alberts et al., 2014). Despite the historical
lack of consensus on methods for isolation, expansion, and
characterization of hMSCs, the International Society for Cellular
Therapy (ISCT) has produced minimal criteria to define hMSCs
(Rosenbaum et al., 2008; Lin et al., 2013). The cells must be
able to:
• Adhere to plastic and develop as fibroblast colony-forming
units and differentiate into cells of mesodermal origin (i.e.,
osteocytes, chondrocytes, and adipocytes). See Figure 1.
• Express the surface markers CD73, CD90, and CD105 during
in vitro culture expansion
• Lack expression of CD11b, CD14, CD34, CD45, CD19, and
HLA-DR surface markers during in vitro culture expansion
It is likely that this definition will continue to evolve to account
for new findings.
Differentiation of MSCs
One of the identifying characteristics of MSCs is their ability
to differentiate into cells of mesodermal origin (Nombela-
Arrieta et al., 2011; Gazit et al., 2014). In addition to this
hallmark trilineage differentiation, there have also been reports
of differentiation toward other cell types of the ectodermal
and endodermal origins, including tenocytes, cardiomyocytes,
skeletal myocytes, smooth muscle cells, and neurons (Tatard
et al., 2007; Galli et al., 2014; Ullah et al., 2015; Youngstrom
et al., 2016). The actual functionality of the end product in this
transdifferentiation is still debated.
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FIGURE 1 | Tri-lineage encompasses differentiation of MSCs. Mesenchymal stem cells are identified by their ability to differentiate into chondrocytes, adipocytes,
and osteoblasts that in turn develop into cartilage, fat tissue and bone. PPARγ is the master regulator of adipogenesis, Runx2 for osteogenesis and Sox9 for
chondrogenesis. Various expression markers are used as indicators of successful differentiation.
Differentiation of MSCs is primarily induced through
media supplementation (and, in some instances, mechanical
stimulation), with different supplements being required for the
various differentiations. Adipogenesis, for example, is induced
through supplementation with dexamethasone, indomethacin,
insulin, and isobutyl methyl xanthine. Osteogenic differentiation
is induced by dexamethasone, ascorbic acid, β-glycerophosphate,
and sometimes bone morphogenic protein 2 (BMP-2) (Ullah
et al., 2015). The completion of differentiation is verified by
checking the expression of characteristic cell type markers,
such as lipoprotein lipase (LPL) for adipogenesis and alkaline
phosphatase (ALP) activity for osteogenesis (Ullah et al., 2015).
More detailed lists of differentiation-promoting components
and the most characteristic markers used to measure level of
differentiation are shown in Table 1.
Differentiation is controlled by an interlinked set of regulatory
molecules forming complex signaling pathways. These pathways
are somewhat distinct between differentiation lineages, although
there are important areas of overlap. This phenomenon is
demonstrated by the inverse relationship that exists between
pathways relating to adipogenic and osteogenic differentiation
(Figure 2). Most differentiation pathways revolve around
regulation of peroxisome proliferator-activated receptor (PPAR),
which is the master regulator of adipogenesis, and runt-related
transcription factor 2 (RUNX2), which is the master regulator
of osteogenesis (Muruganandan et al., 2009; Neve et al., 2011;
James, 2013; Hu et al., 2018). Further details on the most relevant
reported signaling pathways and molecules for each type of
differentiation are provided in Table 1.
Immunomodulation of MSCs
Beyond their potential for differentiation, hMSCs have
remarkable immunomodulatory properties; they possess
the ability to inhibit or promote the immune response of
the host’s body though mediated immunosuppression. These
mechanisms include direct inhibitory effects and other indirect
regulatory effects. This regulatory response involves inhibition
of B and T cell proliferation, cytokine production inhibition,
decreased natural killer (NK) cell activation, and dendritic cell
maturation (Figure 3; Deng et al., 2005; Ma and Chan, 2016;
Cunningham et al., 2018; Wang et al., 2018).
The immunomodulatory response of hMSCs is activated by
inflammatory cytokines (e.g., IFN-γ, IL-1α, IL-1β, and TNF-
α) that are secreted by T cells and other antigen-presenting
cells (Ren et al., 2008; Németh et al., 2009). In response to
their activation, MSCs secrete soluble immune factors capable
of affecting both the innate and adaptive immune systems
by mediating the subsequent regulatory responses of target
cells (Figure 4; Kaundal et al., 2018; Wang et al., 2018).
The immunoregulatory effects mediated in each instance are
dependent on one or more of these secreted factors.
Indoleamine 2,3-dioxygenase (IDO) is one of the well-known
paracrine factors released by hMSCs and has been shown
to promote kidney allograft tolerance (Lan et al., 2010). It
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TABLE 1 | Summary of various inducing components, expression markers, and signaling pathways related to differentiation.
Cell type resulting
from differentiation
Differentiation-inducing
components
Culturing time Relevant expression
markers
Most relevant reported
signaling pathways and
molecules
References
Adipocytes Dexamethasone
Indomethacin Insulin
Isobutylmethyl xanthine
14–21 days, with 2
phases (determination
and terminal
differentiation)
ap2 LPL PPARγ β-catenin dependent Wnt
(anti) Hedgehog (anti)
NELL-1 (anti) BMP (pro)
James, 2013
Cardiomyocytes 5-azacytidine 28 days α-MHC α-cardiac actin
ANP cTnT Desmin
miR1-2 + Wnt/β-catening
(pro) HDAC TGF-β VR-1
5-aza
Solchaga et al., 2011;
Guo et al., 2018
Chondrocytes Ascorbate 2-phosphate
Dexamethasone Insulin
Linoleic acid Selenious
pyruvate Selenium TGF-βIII
Transferrin
21 days, with 2 phases
(pre – induction and
terminal differentiation)
Phase 1: Collagen
types I and II Phase 2:
L-Sox5 Sox6 Sox9
Phase 1 expression
dependent upon: TGF-β1,2
and 3 Phase 2 expression
dependent upon: BMP2
IGF-I TGF-β1 Wnt/β-catenin
(pro) PTHrp (anti)
Mackay et al., 1998;
Antonitsis et al., 2008;
Li and Dong, 2016
Hepatocytes Phase 1: bFGF EGF
Nicotinamide Phase 2:
Dexamethasone Insulin
Oncostatin M Selenium
Transferrin
2 phases: differentiation
(7 days) and maturation
Ullah et al., 2015
Neuronal cells bFGF BME EGF FGF HGF
Insulin LMX1A* NGF
Retinoic acid Valproic acid
Ullah et al., 2015
Osteocytes β-glycerophosphate
Ascorbic acid BMP-2
Dexamethasone
21–35 days ALP COL1 OC ON OP
RUNX2
β-catenin dependent Wnt
(pro) BMP (pro) Hedgehog
(pro) NELL-1 (pro)
TGF-β1 + Wnt/β-catening
(anti)
Neve et al., 2011;
James, 2013
Pancreocytes Actavin A Nicotinaminde
Sodium butyrate Taurine
Ullah et al., 2015
Skeletal/smooth
muscle
NICD TGF-β Ullah et al., 2015
Note that this is not an exhaustive list.
suppresses proliferation and activity of NK and T cells by its
metabolic activity – converting tryptophan into kynurenine.
In humans, IDO synthesis has been reported as a response
of MSCs to pro-inflammatory cytokine production that
suppresses the inflammatory response (Bernardo and Fibbe,
2013; Mbongue et al., 2015; Gao et al., 2016; Kaundal et al., 2018;
Wang et al., 2018).
Another reported soluble factor with immunoregulatory
effects is the unstable oxidative molecule nitric oxide (NO), which
is generated by NO synthase. Inducible NO synthase (iNOS) is
responsible for the immunomodulatory effect of NO. Increased
secretion of NO results in modulation of both the proliferation
and function of T cells. At very high concentrations, it can lead to
the apoptosis of immune cells (Bernardo and Fibbe, 2013; Gao
et al., 2016; Kaundal et al., 2018; Wang et al., 2018). A list of
the known soluble paracrine factors secreted by hMSCs that are
involved in immunoregulation is provided in Table 2, along with
their related effects.
Homing Effects of MSCs
Mesenchymal stromal cells secrete paracrine factors that promote
tissue repair. In response to physical tissue damage, MSCs
secrete factors that allow them to navigate to the site of injury,
referred to as homing (Ullah et al., 2015). An example of a
homing molecules used by MSCs are the chemokine receptors
CXCR4 and CXCR7, which both bind to stromal cell-derived
factor (SDF-1) on endothelial cells; this is a critical step in
facilitating homing of MSCs to various tissues (Ullah et al.,
2019). Homing is generally considered to be beneficial for
tissue repair (Ullah et al., 2015) due to the interaction of
the cells with the host tissue via secretion of trophic and
paracrine factors (Ullah et al., 2015; Moreira et al., 2017).
Engrafting or migration of hMSCs in experimental settings relies
in part on this phenomenon in combination with the direct
delivery of cells.
The homing effect and subsequent migration of hMSCs has
been observed. However, the mechanisms behind it are not well
understood. Only a small percentage of systemically administered
cells manage to reach target tissue and remain there (De Becker
and Riet, 2016; Moreira et al., 2017). For the most part, this
low success rate has been ascribed to low expression levels
of homing molecules, loss of expression of homing molecules
during in vitro expansion, and cultural heterogeneity of the
hMSCs. Cells derived from different sources seem to express
different profiles of the homing molecules (De Becker and Riet,
2016; Moreira et al., 2017).
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FIGURE 2 | The inverse relationship of the main metabolic pathways in OD and AD. Differentiation toward one lineage can inhibit differentiation toward the other.
MSCs as a Novel Tool in Regenerative
Medicine
Regenerative medicine is considered a novel frontier in
medical research (Maienschein, 2011; Sampogna et al., 2015).
It combines the knowledge and application of various fields
such as tissue engineering, cell transplantation, stem cell biology,
biomechanics, prosthetics, nanotechnology, and biochemistry
to replace or restore human cells, tissues, or organs to
their normal functions (Sampogna et al., 2015). A variety
of regenerative medicine therapies are available (see Lonner
et al., 2000; Blais et al., 2013; Zhang X. et al., 2013;
Trushina and Mielke, 2014; Björnson et al., 2016; Moreira
et al., 2017), but their success has been limited by functional
obstacles that increase the risk of harm to patients and
reduce their efficacy as a therapeutic (Neman et al., 2012;
Campana et al., 2014; Goldberg et al., 2017; Cunningham
et al., 2018; Solarte et al., 2018). Despite recent progress, there
is obvious room for improvements regarding both the safety
and efficacy of therapies for patients. The multipotency, high
proliferation potential, paracrine effect, and immunomodulatory
activity of hMSCs (Rosenbaum et al., 2008; Ullah et al., 2015;
Fitzsimmons et al., 2018) have led to development of MSCs as a
tool for use in regenerative medicine. Thus, MSCs are considered
ideal candidates for immunotherapy and tissue engineering.
Recent advancements have allowed researchers to
overcome initial obstacles in the use of MSCs. Numerous
clinical trials have assessed their safety and found that
transfusions using these cells are safe (Neman et al.,
2012; Zhao et al., 2016). Various studies have developed
isolation and culture approaches along with various possible
mechanisms of delivery. These studies have shown that
long-term culture of MSCs is possible without losing the
cells functional, phenotypical, or morphological features
(Bernardo et al., 2007).
Further, MSCs are becoming readily available for biomedical
research. There is growing interest in the use of placental-
and umbilical cord-derived hMSCs due to the relatively high
availability of discarded tissue associated with births (Moreira
et al., 2017); however, the variance in phenotypic properties
(if any) between hMSCs derived from different sources is an
important open question. Bone marrow- (BM-) and adipose
tissue-derived (Ad-) hMSCs are the most favored stem cell
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FIGURE 3 | The immunoregulatory effects of hMSCs on immune cells.
types in both tissue engineering and cell-based medicine
for a variety of reasons, despite the invasive procedures
required for tissue collection (Fitzsimmons et al., 2018): (1)
the total cell number that can be harvested each time is
higher than with other stem cells; (2) the frequency of
cells of interest is higher than with other stem cells; and
(3) Ad-hMSC harvesting can be performed as part of some
elective cosmetic surgeries (e.g., liposuction) (Fitzsimmons
et al., 2018). Ad-hMSCs have been shown to have increased
capacity for adipogenic differentiation in vitro, while BM-
hMSCs have increased capacity for osteogenic and chondrogenic
differentiation (Liu et al., 2007). Through a comparative study
on the immunomodulatory abilities of cells derived from
the same donor bit different tissues, Valencia et al. (2016)
determined that Ad-hMSCs have a higher capacity for inhibiting
dendritic cell differentiation than do BM-hMSCs, while BM-
hMSCs displayed a higher capacity for inhibition of NK cell
cytotoxic activity; these results have been corroborated by several
independent groups (Ivanova-Todorova et al., 2009; Blanco et al.,
2016). These observations—whether relating to proliferation
potential or direct therapeutic application abilities—highlight the
importance of choosing the optimal cell source for a particular
clinical circumstance.
Efficacy of Cell Engraftment vs. Paracrine Factors
For the last several decades, the therapeutic potential of hMSCs
has been focused on cell transplantation, adding hMSCs to a
recipient donor site for repair via regeneration, differentiation,
and immunomodulation (Lukomska et al., 2019). Co-culturing
in animal studies has shown that hMSCs can induce tissue
regeneration to some extent in the heart (Rose et al., 2008),
kidneys (Qian et al., 2008), and liver (Cho et al., 2009)
through infiltration and replacement in damaged or injured
tissue by multipotent hMSCs (see Figure 5). Increasing attention,
however, has lately been given to the immunomodulatory and
suppressive capabilities of hMSCs, especially with regards to
their paracrine factors (Németh et al., 2009; Cunningham et al.,
2018; Kaundal et al., 2018). Currently, approximately 10% of the
clinical trials registered in the United States are using MSCs to
study immunological disease. Through their ability to decrease
inflammation and general inhibitory functions, hMSCs have been
utilized as contributing factors for various immune disorders for
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TABLE 2 | A list of inflammatory cytokines that activate immunoregulatory state of
hMSCs, major known soluble paracrine factors secreted by hMSCs, and a
summary of their biological functions.
Immunosuppressive
factors secreted by
MSCs
Summary of biological
function
Activating
inflammatory
cytokines
CCL2 Promotion of monocyte
migration. Suppression of
activation and mitigation of
TH17 cells.
IFN-γ, IL-1α, IL-1β,
TNF-α
Galectins Suppression of the
immunomodulatory effects of T
cells.
IDO Suppression of the effects and
proliferation of immune cells.
IL-10 Suppression of immune cell
apoptosis.
NO Promotion of immune cell
apoptosis. Suppression of
proliferation and modulation of
T cells.
PGE2 Suppression of NK cell cytolytic
activity and T cell proliferation.
TSG6 Overall anti-inflammatory effect.
TGF-β Inhibition of mast cell
degranulation, NK cell
activation and proliferation, and
Treg induction.
symptom relief. Such disorders include type 1 and type 2 diabetes
(Moreira et al., 2017), acute graft versus host disease (GvHD)
(Gao et al., 2016), arthritis (Burke et al., 2016), allograft rejection
(Munir and McGettrick, 2015), and Crohn’s disease (Ibraheim
et al., 2018). The possible immunomodulatory effects of hMSCs
have been found to be dependent upon the source of the hMSCs
as well as their immediate microenvironment (Bortolotti et al.,
2015). The microenvironment is dependent upon the individual
inflammatory profile of the host, which is potentially related to
any disease pathogenesis present. This variability leads to varied
cytokine profiles that are, at least in part, responsible for the
difficulties of using MSC therapy effectively in both preclinical
and clinical situations (Kaundal et al., 2018). Some of these
challenges may be overcome by personalizing each case (i.e.,
tailoring each therapy to the inflammatory environment of the
recipient patient).
There has been a recent paradigm shift away from the
primary aim of hMSC transplantation being tissue repair by
engraftment toward the use of hMSCs to promote healing
via their secretion of paracrine factors. In many therapeutic
contexts, it is now recognized that MSCs exert their healing
effects through paracrine signaling and cell-to-cell contact, not
by replacing cells (Fitzsimmons et al., 2018). There are a few
notable examples using hSMCs as paracrine-mediated treatment
currently in development (Amorin et al., 2014; Hofer and
Tuan, 2016; Archambault et al., 2017; Moreira et al., 2017;
Cunningham et al., 2018; Ibraheim et al., 2018; Solarte et al.,
2018). The reported success of these studies indicates that the
FIGURE 4 | The immunoregulatory secretome of hMSCs. Known soluble
factors secreted by MSCs upon activation by T cells and other antigen
presenting cells are shown.
MSC secretome exerts beneficial effects that may be exploited by
therapeutic applications.
Existing Challenges and Problems
Despite the initial successes demonstrated in animal and early
clinical trials regarding the safety and efficacy of hMSCs, a
number of challenges, problems, and unanswered questions
remain. In order for in vitro cultured MSCs to engraft after
implantation or to secrete their beneficial factors, they must
be able to survive. The transplantation procedure itself exerts
various direct mechanical and chemical stresses on the cells,
and the treated tissue offers a comparatively much harsher
environment than the standard culture surroundings that cells
experience in vitro. In tissues in vivo, there are various negatively
impacting stressors, such as hypoxia, inflammation, decreased
energy/nutritional availability, and high acidity. Various
strategies to enhance survival and overcome these adverse
conditions have been developed, including preconditioning,
genetic modification, and supportive biomaterials as a delivery
device (Baldari et al., 2017; Moreira et al., 2017).
It is possible that donor variability and differences in isolation
site have an effect on experimental outcomes, though the extent
of these effects is not yet well understood. This uncertainty may
be exacerbated by heterogeneity in the origins of MSCs used
in tests (Bortolotti et al., 2015; Lukomska et al., 2019). Further,
there is a lack of knowledge of the optimal dose and frequency
required for hMSC transplantation (Lee, 2018; Lukomska et al.,
2019). In addition, generating high doses of hMSCs requires
cellular expansion on a large scale. Despite being proven to
retain their characteristics over long term expansion (Bernardo
et al., 2007), MSCs eventually become senescent (Turinetto et al.,
2016). Senescent cells have undergone functional changes. Firstly,
differentiation potential usually decreases due to accumulation
of oxidative stress and dysregulation of key differentiation
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FIGURE 5 | Examples of therapeutic applications for hMSCs, including organs where cell transplants have been used for engraftment, some autoimmune disorders
where the immunoregulatory and differentiation abilities of hMSCs have been utilized, and some of the paracrine factor-mediated influences that can be used in a
therapeutic setting.
regulatory factors. Secondly, both migratory- and homing-related
abilities of hMSCs are reduced as they move into senescence.
Finally, the secretome of hMSCs becomes compromised in
senescence. Many of the factors that are present in the senescent
MSC secretome can exacerbate an inflammatory response at a
systemic level and so promote either migration or proliferation
of cancer cells (Turinetto et al., 2016).
In many cases of MSC transplantation, there is little to no
integration of the transplanted cells, and cells that are retained
are observed to have a short survival time in some cases (Li
et al., 2016; Lukomska et al., 2019). Even though more than
two thousand patients have received either autologous or culture
expanded allogeneic MSCs, long-lasting observations are lacking
in many cases (Lukomska et al., 2019). This lack of data indicates
that more progress is difficult. Tumor support due to the
immunosuppressive effects of MSCs and the related possibility
of tumorigenicity of such a therapy has been reported (Barkholt
et al., 2013). There have also been reports of BM-hMSC-induced
liver fibrosis (Russo et al., 2006). These issues must be addressed
by long-term studies regarding safety of use.
While the use of hMSCs holds great promise in regenerative
medicine, the hurdles and unanswered questions outlined in
this section still linger. perhaps the greatest barrier preventing
widespread and successful implementation of hMSCs as tools
to enhance and develop therapeutics is the critical gap in
knowledge of hMSC metabolism. During differentiation, we can
observe a metabolic shift in hMSCs from using only glycolysis
to a mix of glycolysis, oxidative phosphorylation, and beta
fatty acid oxidation to produce energy. However, in order to
have immunomodulatory effects (via paracrine factors) on a
host‘s immune system, hMSCs must be mainly in a glycolytic
state. Further, it is not well understood to what extent energy
metabolism is mixed at different stages of differentiation (early
versus late) or whether it is dependant upon the type of
differentiation the cells are undergoing. An understanding of how
cell source and age affects differentiation and if different states
affect the survival and function and, therefore, usability of cells
in vivo. In the following section, we delve into some of these gaps
and discuss how acquiring a deep understanding of underlying
mechanisms can help unlock the therapeutic potential of hMSCs
in regenerative medicine.
METABOLISM OF MSCs
MSC Function Is Linked to Metabolism
The proliferation, differentiation, and immunomodulatory
functions of hMSCs are linked to cellular metabolism
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(dos Santos et al., 2010; Estrada et al., 2012; Beegle et al.,
2015). Emerging evidence suggests that hMSCs are metabolically
heterogeneous and that these differing metabolic states impact
both differentiation ability and capacity for immunomodulation
(Agathocleous and Harris, 2013; Liu et al., 2019). To date, studies
have focused primarily on BM-hMSCs and Ad-hMSCs.
There is strong evidence suggesting that, in their
undifferentiated state (while undergoing proliferation),
hMSCs rely primarily on glycolysis for energy production.
This phenotype has been demonstrated in BM-hMSCs, which
show a preference for glycolysis during proliferation (Pattappa
et al., 2011; Buravkova et al., 2013; Shum et al., 2016; Zhu and
Thompson, 2019) but shift to a more oxidative phosphorylation
(OxPhos)-dependent metabolism during osteogenic and
adipogenic differentiation (OD, AD) (Meleshina et al., 2016;
Shum et al., 2016). Similar findings have been reported for Ad-
hMSCs (Meleshina et al., 2016; Meyer et al., 2018). Proliferating
Ad-hMSCs were found to have a preference for glycolysis even
under aerobic conditions, while during OD the cells increased
both glycolysis and mitochondrial metabolism, including the
processes of OxPhos and fatty acid β-oxidation. However,
when Ad-hMSCs underwent AD, they showed a decreased
capacity for the pentose phosphate pathway (PPP) and glycolysis,
while mitochondrial enzyme activities increased, indicating an
increased capacity for oxidative phosphorylation and β-oxidation
(Meleshina et al., 2016; Meyer et al., 2018).
The ability of BM-hMSCs to differentiate has also been shown
to be affected by mitochondrial functions (Zhang Y. et al., 2013;
Li et al., 2017). Consistent with reports that proliferating hMSCs
have a glycolytic phenotype, undifferentiated cells have high
levels of hypoxia-inducible factor 1 (HIF-1), a transcriptional
regulator central to regulation of genes that are involved in
hypoxic responses. It is also a crucial physiological regulator
of anaerobic metabolism (Gaspar and Velloso, 2018). Cells
undergoing OD downregulate HIF-1. Downregulation of HIF-1
seems to be required for the activation of mitochondrial OxPhos,
an oxygen-dependent pathway (Shum et al., 2016).
The mitochondria of hMSCs seem to be primarily inactive
while cells remain in their proliferation stage, during which
metabolic pathways related to glycolysis and its associated
signaling pathways required for adenosine triphosphate (ATP)
generation and general anabolitic activity are most active (see
Table 3). Glycolytic metabolism also seems to be a requirement
for hMSCs to be able to sustain immunosuppressive factor
secretion (Liu et al., 2019). Secretion of immunomodulatory
factors is only possible when hMSCs have been activated,
such as by IFN-γ (Waterman et al., 2010). Liu et al. (2019)
utilized IFN-γ treatment to cause immune polarization in hMSCs
leading to remodeling of metabolic pathways toward glycolysis
(reducing TCA cycle metabolism), a requirement for sustained
immunosuppressive factor secretion. The activated cells were
measured to have increased lactate levels, glucose consumption,
and acidification rate. Increased expression of glucose transporter
1 and hexokinase isoform 2 (key enzymes in glycolysis), along
with reduced electron transport and OxPhos, was also observed.
These are all indicators of increased glycolytic activity (Liu et al.,
2019). MSCs with a glycolytic phenotype are also able to sustain
TABLE 3 | List of common signals in metabolism and the major metabolic
pathways effected.
Signal Metabolic pathways regulated by the signal
AMPK Inhibition of glycolysis and fatty acid synthesis. Promotion of
fatty acid oxidation.
Hedgehog Stimulation of glycolysis.
HIF Redirection of energy metabolism from OXPhos to glycolysis.
mTOR Stimulation of glycolysis, lipid synthesis, protein synthesis, and
pyrimidine synthesis.
Myc Stimulation of glycolysis, glutaminolysis, and nucleotide
synthesis.
PI3K Stimulation of glucose uptake, fatty acid synthesis, and
glycolysis.
Ras Stimulation of glucose uptake and PPP. Regulation of
glutaminolysis.
Sirtuins Regulation of TCA cycle, glycolysis, and fatty acid oxidation.
IDO production and the exposure to IFN-γ inhibited activity of
the mitochondrial electron transport chain (complexes I or III),
blocking OxPhos and reducing mitochondria-related reactive
oxygen species (mROS). This reduces the effects of mROS that are
key to metabolic remodeling in differentiation. Liu et al. (2019)
further showed that Akt/mTOR signaling pathway activation is
required to induce metabolic reconfiguration, specifically IDO
and Prostaglandin E2 (PGE2) production. PGE2 increases in
response to increased aerobic glycolysis. The immune response
of hMSCs treated with IFN-γ is altered if the metabolic
reconfiguration induced by Akt/mTOR is disrupted.
The effect of interferon regulation on hMSC metabolism can
be varied. IFN-γ has also been used to inhibit proliferation and
alter AD, OD, and neural differentiation (ND) by activating
IDO (Croitoru-Lamoury et al., 2011). The kynurenine pathway
(KP), along with IDO1 and IDO2, is expressed in hMSCs and
highly regulated by both IFN-γ and IFN-β. IFN-γ licensing
of hMSCs results in inhibited proliferation via activation of
the KP and subsequently IDO, and inhibits the cell potential
for OD and AD. In contrast to IFN-γ licensing, IFN-β
treatment managed to increase expression of adipogenic markers
(Croitoru-Lamoury et al., 2011).
IFN-β has been shown to enhance immunomodulatory
functions of hMSCs in other reports. Vigo et al. (2019)
demonstrated IFN-γ induced expression of secretory leukocyte
protease inhibitor (SLPI) and hepatocyte growth factor (HGF),
soluble mediators that are involved in both immune and
regenerative functions of hMSCs. Simultaneously, IFN-β induced
the activity of mTOR, increasing the glycolytic capacity of the
cells. This energy metabolic modification improved the cells’
ability to control T cell proliferation, yet another indication of
a link between high glycolytic capacity and immunomodulatory
capabilities (Vigo et al., 2019).
Overall reports discussing hMSC metabolism seem to, for
the most part, agree that during proliferation the cells primarily
generate ATP through glycolysis. However, upon initiation
of differentiation, cells seem to turn toward mitochondrial
metabolism, with reported increases in metabolism and
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biogenesis indicating the importance of mitochondrial activity
when it comes to hMSC functionality (Shum et al., 2016).
There is not much known about whether amino acid
metabolism is affected during functional progression of hMSCs
or what effects they induce if modified through metabolic
changes. For example, El Refaey et al. (2015) studied the aromatic
amino acids tryptophan and tyrosine, finding that oxidation
(via cell senescence) disrupted their anabolic effects on BM-
MSCs. By using mouse BM-MSCs, they were able to examine
effects of oxidized dityrosine and kynurenine of proliferation
and differentiation and found that these oxides inhibited BM-
MSC proliferation, ALP expression and activity and expression
of osteogenic markers. Yue et al. (2018) studied fatty acid
related gene expression and compositions of fatty acids during
adipogenesis of bovine Ad-MSCs and found that lipid-related
gene expression and fatty acid composition changed noticeably
during the early stages of differentiation (e.g., there was increased
expression of de novo lipogenesis-related genes, and thus de novo
lipogenesis produced fatty acid elongation and desaturation)
before returning to normal (e.g., proportions of saturated fatty
acids, monounsaturated fatty acids, and polyunsaturated fatty
acids returned to initial levels in later stages). Their conclusion
was that de novo lipogenesis and desaturation comprised
the major fatty acid flux during adipogenic differentiation
of bovine Ad-MSCs.
Ornithine decarboxylase (ODC) and polyamine biosynthesis
are important in the proliferation of stem cells (Tsai et al.,
2015). The role of ODC regarding differentiation has not been
fully explored but is considered to be diverse. Through
the study of inhibition of ODC’s irreversible inhibitor,
α-difluoromethylornithine, Tsai et al. (2015) hypothesized
that inhibition of ODC and the accompanying depletion of
exogenous polyamines might be correlated with the osteogenic
induction of BM-hMSCs, and demonstrated (in BM-hMSCs)
that decreases in the expression of PPAR- γ and ODC along with
an accompanying reduction in polyamines, are responsible for
enhanced osteogenesis.
MSC Functionality Is Greatly Impacted
by Mitochondrial Activity
As suggested in section “MSC Function Is Linked to Metabolism,”
active mitochondria are necessary for successful differentiation.
Accumulating evidence indicates that mitochondrial enzymes
and regulatory pathways are of great importance for MSCs
in proliferative and differentiating states (Chen et al., 2008;
Buravkova et al., 2013; Li et al., 2017). Mitochondria have
been found to be crucial for sufficient ATP production
to support OD, in addition to other mechanisms. Active
mitochondria support OD by promoting β-catenin acetylation
and, therefore, its activity. β-catenin is an important signaling
pathway in osteogenesis (Shares et al., 2018). In osteogenesis,
a mechanism of OD induction is to induce mitochondrial
OxPhos by replacing glucose with galactose. This switch
also stimulates β-catenin signaling and β-catenin acetylation.
Increased β-catenin acetylation is the mechanism of osteogenesis
driven by mitochondrial OxPhos (Shares et al., 2018). This
acetylation increases during osteogenesis (BM-hMSCs). Active
mitochondria may also support other osteogenic pathways by
providing acetyl groups.
Other enzymatic activity has been confirmed that further
supports the importance of mitochondrial activation for MSC
functionality. Creatine kinase (CK) activity, which is involved
in buffering and recovery of ATP, has been reported in Ad-
hMSCs. It stimulates glycogenolysis by increasing cytoplasmic
concentration of inorganic phosphate. Activity of CK was found
in both differentiated and proliferating Ad-hMSCs, with more
mitochondrial CK activity in AD cells. This further supports
the theory of a shift toward oxidative metabolism/mitochondrial
metabolism during differentiation of MSCs (Meyer et al., 2018).
Through the reversible mitochondrial nicotinamide adenine
dinucleotide phosphate (NADP)-dependent reaction of isocitrate
dehydrogenase (NADP-IDH), an anaplerotic pathway exists
that forms isocitrate from glutamine through a process
called glutaminolysis. Through this pathway, glutamine can
compensate for the lack of glucose for both ATP production
and anabolic precursor supply (Smolková and Ježek, 2012). This
pathway is active in MSCs during OD, indicating yet another
important role that mitochondria play when it comes to provision
of sufficient ATP to ensure successful differentiation.
Reactive oxygen species (ROS) are known to serve as signaling
molecules capable of regulating biochemical pathways that are a
part of normal cell function. They are particularly important in
metabolism and inflammatory signaling (Forrester et al., 2018).
Regulation of mROS levels also contributes to determination of
differentiation outcome. For a long time, these molecules were
considered to be harmful to cells, inducing organismal death and
dysfunction, but more recent reports suggest that excess mROS
impair OD and promote AD by inhibiting Hedgehog signaling
(a pathway essential for bone development and maintenance)
(Li et al., 2017).
Possible Ways to Achieve Metabolic
Manipulation
Since functionality and survival of hMSCs is affected by changes
in their metabolism, there is the potential to enhance the
efficacy of hMSC therapies through manipulation of metabolism.
hMSCs can effectively reconfigure metabolism to respond to
the biochemical demands of tissue repair, be it secretion of
immunomodulatory factors or integration and differentiation
toward tissue specific cell types (Mylotte et al., 2008; Zhu et al.,
2014; Yuan et al., 2019). Currently, the most extensively studied
subtypes are BM-hMSCs and Ad-hMSCs, but even these subtypes
have not been exhaustively studied. Evidence indicating the
importance of both the enzymes and mitochondrial pathways
support its significance for proliferation and differentiation of
hMSCs (Chen et al., 2008; Buravkova et al., 2013; Li et al.,
2017). In addition, several critical MSC functions are not only
influenced by internal cellular mechanisms, but also by external
ones (mechanical and biochemical) such as the composition of its
microenvironment (Bloom and Zaman, 2014). Previous work has
explored various ways of affecting the mechanisms controlling
MSC metabolic function (see Figure 6).
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FIGURE 6 | Possible ways to achieve metabolic manipulation of hMSCs. The resulting effects may vary depending on the original cell source.
One such approach is to alter the functional capacity of
MSCs through oxygen manipulation, due to the importance
of mitochondria and mROS discussed above. Muñoz et al.
(2014) investigated the effect of oxygen levels on metabolic
phenotypes of hMSCs. Oxygen is a ubiquitous regulator of
cellular metabolic activity and of the survival, function, and
differentiation of hMSCs. Using both normoxic and hypoxic
conditions, they found contrasting metabolic profiles for hMSCs
during proliferation versus OD. The key difference was found
in the coupling of glycolysis to the TCA cycle, glutaminolysis,
and malate-aspartate shuttle. In response to low oxygen
levels, undifferentiated hMSCs showed increased consumption
of both glucose and glutamine that activated the malate-
aspartate shuttle in order to accommodate increased cytosolic
production of nicotinamide adenine dinucleotide + hydrogen
(NADH) and transport glutamate and reducing equivalents
into the mitochondrial matrix for oxidation (Muñoz et al.,
2014). Low oxygen also activates HIF-1, reducing pyruvate
dehydrogenase activity so that transport of glucose derived
carbons into the TCA cycle decreases (Estrada et al., 2012).
These metabolic characteristics allow increased proliferation
under hypoxic circumstances, allowing cells to survive in an
ischemic environment.
Similar findings were reported for proliferation of cells grown
under hypoxia (dos Santos et al., 2010). For cells in OD, hypoxia
induces a more significant block of carbon flow from glycolysis
into the TCA cycle, compared to undifferentiated cells. This is
demonstrated by a greater rise in lactate levels. The carbon flow
blockage results in lower citrate levels and less production of
reduced cofactors [e.g., NADH and flavin adenine dinucleotide
(FADH2)] involved in OxPhos. The lower citrate levels indicate
a more pronounced metabolic uncoupling of glycolysis and
TCA cycle for cells in OD compared to undifferentiated cells
(Muñoz et al., 2014). This observation of a tight coupling of
glycolysis and TCA cycle in cells undergoing OD compared
to proliferating hMSCs suggests a stronger dependence on
oxygen during OD (Muñoz et al., 2014). This dependency has
been shown independently (Buravkova et al., 2013). Permanent
oxygen deprivation resulted in the attenuation of cellular ATP
levels, leading to diminished mitochondrial ATP production and
stimulation of glycolytic ATP production. The attenuated cellular
ATP levels stimulated a proliferation state of the hMSCs and
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reduced the differentiation capacity, indicating that low ATP
levels (arising from glycolysis only) are sufficient to maintain the
cells’ uncommitted state (Buravkova et al., 2013). Hypoxia has
also been used to precondition MSCs to enhance their survival
and cell retention in vivo via induction of metabolic changes
(Beegle et al., 2015).
Reactive oxygen species are known to play a role in the
mediation of both pathophysiological and physiological signal
transduction (Forrester et al., 2018). The subcompartments in
cells (e.g., peroxisome and mitochondria) that produce ROS
are often associated with metabolism. Mitochondria-related ROS
are able to influence metabolic processes on their own, and
so have an effect on differentiation and immunomodulation
of hMSCs. Studies have shown that by using mitochondrial-
targeted antioxidants, AD may be inhibited; however, as
mentioned in section “MSC Functionality Is Greatly Impacted by
Mitochondrial Activity,” excess mROS impair OD and promote
AD by inhibiting Hedgehog signaling (Li et al., 2017). The
role of mROS in chondrogenic differentiation (CD) is less well
known (Li et al., 2017). Takarada-Iemata et al. (2011) found
that through sustained exposure to glutamate, a significant
decrease in osteoblastic marker expression could be induced.
This happened in association with a reduction of intracellular
glutathione (GSH) levels, but without affecting adipogenic
marker expression. This finding suggests that extracellular
glutamate preferentially suppresses osteoblastogenesis over
adipogenesis in MSCs through the cysteine/glutamate antiporter
(Takarada-Iemata et al., 2011).
The effects of other chemical stimuli have also been reported.
In contrast to the inhibiting effects of extracellular glutamate
on OD, it was reported that by inducing overexpression of
heme oxygenase-1 (HO-1) OD of BM-hMSCs may be enhanced
and adipogenesis decreased (although no mechanism was
determined) (Barbagallo et al., 2010). HO-1 is a nuclear factor
erythroid 2-related factor 2 (Nrf2)-regulated gene that plays a
critical role in preventing vascular inflammation. It also has
important antioxidant, anti-inflammatory, antiproliferative, and
antiapoptotic effects in vascular cells (Araujo et al., 2012).
Recent reports suggest that frozen or cryopreserved hMSCs
are therapeutically less effective than freshly harvested MSCs
(François et al., 2012). It seems that dimethyl sulfoxide (DMSO),
a commonly used cryopreservative solution, decreases metabolic
and immunosuppressive properties of hMSCs, while valproic
acid (VPA) pre-treatment enhances both (François et al., 2012).
Moreover, the T cell suppressive capacity of hMSCs in vivo is
related to the cells’ glycolytic and respiratory capacity, in contrast
to their IDO dependence in vitro. This observation, therefore,
leads to speculation that hMSCs may only be able to induce
immunoregulatory effects when undifferentiated.
Metabolism in MSCs is a complex and dynamic system. We
have outlined several gaps in the collective knowledge of MSC
metabolism that are actively being addressed by the community.
As we gain insights into questions regarding the primary energy-
generating pathway(s) utilized during differentiation, we will
move closer to manipulating these systems. However, we will
need a holistic perspective that integrates knowledge at the
various biological levels of MSC differentiation.
MATHEMATICAL MODELING OF HUMAN
METABOLISM
A bottom-up systems biology approach allows for a mechanistic
understanding of a system (Westerhoff and Palsson, 2004). Such
mathematical models can predict potential interventions,
potentially providing insights into how to successfully
manipulate MSCs for therapeutic applications. Over the
last few decades, many individual components of MSC
biology have been studied in detail. However, to predict
a cell’s phenotype, it is necessary to understand all of the
systemic interactions of environmental and cellular components
that contribute to that phenotype (Bordbar et al., 2014).
A combination of high-throughput -omics technologies,
enabling the collection of large data sets, and improved
computational modeling methods to holistically analyze that
data have made systems biology possible (Henry et al., 2010;
Resendis-Antonio, 2013).
The first step in modeling metabolism at the genome-
scale is to reverse engineer the network structure (Reed and
Palsson, 2003; Resendis-Antonio, 2013; Bordbar et al., 2014;
Yurkovich and Palsson, 2016). This reconstruction process starts
with collecting all annotated components of the genome and
experimental evidence of biochemical reactions for the organism
of interest (Thiele and Palsson, 2010). Further constraints are
placed on the network based on biochemical knowledge—
including stoichiometric constraints (e.g., mass and charge
balance of reactions), thermodynamic constraints, and enzymatic
capacity constraints (Reed and Palsson, 2003; Rocha et al., 2008;
Oberhardt et al., 2009; Thiele and Palsson, 2010)—eventually
resulting in a genome-scale model (GEM) of metabolism
(see Figure 7). Transcriptomic and proteomic data is then
used to select which of these reactions are active in a given
phenotype, based on the presence of the enzyme that catalyzes
the reaction. Metabolomic data may be used to constrain
which metabolites should be produced or consumed by the
cell being modeled (Bordbar et al., 2017). The resulting GEM
can then be used with a variety of computational approaches,
such as flux balance analysis (FBA), to determine the flux
state (i.e., pathway usage) of the entire metabolic network (see
Figure 8).
This ability to integrate information from multiple types
of -omic data with previously acquired detailed biochemical
data makes metabolic modeling a powerful technique to answer
biological questions regarding how phenotypes occur due to
genetic mutation or environmental perturbations (Thiele and
Palsson, 2010). As further data is obtained, the model will
more closely represent the intended physiological conditions.
An updated model may produce novel hypotheses which can
suggest new experimental directions. Establishing this feedback
between experimental design and computational evaluation is
valuable and enables a better understanding of how cells—
including MSCs—organize their metabolic system in response
to shifts in environment and functional demands (Reed and
Palsson, 2003; Resendis-Antonio, 2013). Furthermore, the ability
to contextualize models based on information at various levels
from genomic to environmental has the potential to allow models
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FIGURE 7 | The process of reconstructing a genome-scale metabolic model (GEM). Using a base human metabolic reconstruction along with experimental data and
biochemical databases (e.g., KEGG or BiGG), a constraint-based model can be created. From this model, a GEM is derived, from which cellular functions can be
studied. Newly acquired knowledge from the GEM can be used to create cell experiments to further validate or improve the model. The validated GEMs can then be
used to further study cells for use in regenerative medicine.
to inform personalization of medicine, for example by predicting
potential genetic markers of a successful MSC donor.
Existing Human Models
Genome Annotation Efforts Led to the First Human
Metabolic Reconstructions
Various community-driven efforts have led to several
reconstructions of the global human metabolic network
(Romero et al., 2004; Duarte et al., 2007; Ma et al., 2007;
Agren et al., 2012; Thiele et al., 2013; Mardinoglu et al., 2014).
Compiling data on all reactions that have been linked to genes
annotated in the human genome from various databasesas
having metabolic activity is a substantial task, and important to
the quality of subsequent work (Kanehisa et al., 2016; Norsigian
et al., 2020). This production of annotated human genomes
allowed, for the first time, metabolic networks that cover the
entire human metabolic repertoire to be produced. Between 2005
and 2012, the first four human metabolic reconstructions were
produced; humanCyc (Romero et al., 2004), Recon1 (Duarte
et al., 2007), Edinburgh Human Metabolic Network (EHMN)
(Ma et al., 2007), and Human Metabolic Reconstruction (HMR)
(Agren et al., 2012). Each of these networks expanded on
the previous work, including more reactions and better links
between reactions and genes, allowing for improved analysis of
expression data. Further improvements were made in Recon2
(Thiele et al., 2013) and HMR2 (Mardinoglu et al., 2014) and
their updates (Smallbone et al., 2013; Quek et al., 2014; Sahoo
et al., 2014, 2015; Swainston et al., 2016). By expanding the
extent of the reaction coverage, increasing the detail of the
available gene-to-reaction links, and placing more emphasis
on the inclusion of good thermodynamic and stoichiometric
information, better possibilities for accurate simulations were
afforded; thus, these models represent significant steps forward.
In addition, tools such as PathwayBooster and Path2Models
have allowed the utilization of data bases such as KEGG in the
automated reconstruction of new or custom built networks.
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FIGURE 8 | Going from a large base model to a cell specific GEM. (A) Genome scale metabolic models build on the gene-protein reaction association and represent
a set of reactions as a matrix with linked genes. Synthesis of metabolites is designated by a positive number and breakdown with a negative number. (B) Going from
a large base model to a cell/condition specific model. (1) A relevant base model is chosen. This model is a summary of known metabolic reactions and forms a
species specific metabolic reconstruction. This base model usually has the highest count of genes, reactions and metabolites. (2) A process aiming at reducing the
size of the model starts. By considering biochemical and biophysical constraints, e.g., thermodynamic feasibility, some reactions stop being reversable and the
reconstruction becomes a model. Other constraints applied at this stage relate to stoiciometricity and enzyme capacity. The number of genes, reactions and
metabolites is reduced. (3) Data about transcripts and proteins present in a cell type and the availability of nutrients in medium lead to the removal of yet more
reactions. A cell specific model is created. (4) Metabolomic data specific to the condition the cell is supposed to represent allows the magnitude of reactions to be
predicted. Some will have higher flux rates than others. More reactions may be removed at this stage. The model now becomes condition specific.
The Latest Human Metabolic Reconstructions
Contain New Dimensions of Information
Recon3D is the latest update of the Recon family of human
metabolic network reconstructions (Brunk et al., 2018). The
key novel attribute of this reconstruction is that it includes
information regarding protein and metabolite structures. In
addition, the number of reactions included in the reconstruction
has almost doubled from the previous version, to 13,453 total
reactions. The inclusion of three-dimensional (3D) structural
information has allowed Recon3D to be used to show that
deleterious mutations map to specific areas of the genome.
By using this information, improved predictions of cancer-
related mutations may be made compared to previous Recon
models, which include a less detailed mapping of genes. The 3D
aspect of the protein and metabolite information in Recon3D
has also been used to investigate the metabolic effects of
various drugs; this analysis revealed that drug effect signatures
often contained disparate functional domains and metabolites,
indicating that many drug effects are due to compensatory
downstream metabolic effects (Brunk et al., 2018). Recon3D
has been constructed in such a way as to allow for integration
with the AGORA platform for modeling the gut microbiome
by using a consistent set of identifiers (Magúsdóttir et al.,
2017). As it becomes increasingly clear that the microbiome
plays an important part in human health, being able to
include cometabolism by human and microbial cells is a very
useful feature (Magúsdóttir et al., 2017). A global network
reconstruction can then provide the starting point for the
production of tissue-, cell-, or condition-specific GEMs.
Current State-of-the-Art Applications
Generic Human Metabolic Reconstructions Can Be
Analyzed to Gain General Metabolic Insights
A base GEM may be utilized to produce general predictions
about whole human metabolism, providing useful insights into
both human health and predictions of currently unknown human
metabolic functions.
The various human models have been used to predict
biomarkers for inborn errors of metabolism (the accuracy of
previous predictions feeds into improving these models) (Kell
and Goodacre, 2014). Inborn errors of metabolism (IEMs) are
a collection of hereditary metabolic defects found in most of
the main human metabolic pathways. These defects are usually
screened for in infants by way of biofluid metabolomics (i.e.,
metabolomics analysis of either dried blood samples or urine).
Early recognition and treatment of IEMs is very important. The
current method detects specific biomarkers that have altered
concentrations due to known genomic mutations. Identifying
good biomarkers is key to successful early diagnosis. With
the advent of the human metabolism genome-scale network
model, a novel computational approach was developed that could
systematically predict altered or affected metabolic biomarkers.
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This possible use of GEMs has the potential to extend the
information that can be inferred from the data, enabling accurate
diagnosis for each individual patient, further insight of hot
spots in human metabolism with respect to IEMs, and discovery
of novel IEMs (expanding the range of disease-associated
metabolites). By making use of the GEM, gene-protein-reaction
(GPR) metabolic pathways relevant to a specific genotype-
phenotype pair can become more feasible, meaning that disease-
specific biological insights can be derived (Shlomi et al., 2009;
Sahoo et al., 2012; Mandal et al., 2018; Mussap et al., 2018).
By analyzing reactions in Recon1 that were defined as being
present due to genome annotation or literature data, but that
were not predicted to be active, and then adding surrounding
reactions to activate them, predictions have been made about
previously unknown human metabolic functions such as that of
iduronic acid following glycan degradation, N-acetylglutamate in
amino acid metabolism, and the human activity of gluconokinase
(Rolfsson et al., 2011; Paglia et al., 2016). Such information
will improve future metabolic studies both computationally and
in the laboratory.
Reconstructions can be made specific by integrating -omics
data
Once a base GEM has been selected, there are a variety of
methods available to make the model specific to a particular cell
type and circumstance by integrating transcriptomic, proteomic,
and metabolomics data. These context-specific models are able
to provide more detailed insights into human metabolism in a
particular cell type, and comparison of models is particularly
useful. Previous context-specific human models have produced
useful insights into healthy and diseased metabolism.
A cell’s metabolic capabilities are defined by which enzymes
it expresses. Transcriptomic and proteomic data provide
information about the enzymes expressed under certain
circumstances. Both of these data types correlate to enzyme
activity, although not perfectly (Munir and McGettrick, 2015;
Ibraheim et al., 2018). Several methods to prune a GEM based on
expression data, mostly transcriptomics, have been developed.
Although there are numerous technical differences, all seek to
balance the retention of reactions known to be or likely to be
present in a particular cell type, based on expression data or
prior knowledge, while removing extraneous reactions. GIMME
(Moreira et al., 2017), iMAT and INIT (Antonitsis et al., 2008;
Vigo et al., 2019), and MBA, Fastcore, and mCADRE (Ullah et al.,
2015; Archambault et al., 2017; Fitzsimmons et al., 2018) are all
commonly used (Rosenbaum et al., 2008; Neman et al., 2012).
Another way to make models more context specific is to use
metabolomic data collected by mass spectrometry or NMR to
constrain what the model takes up or secretes to realistic values.
By either measuring changes in the concentration of various
metabolites in the medium over time or by comparing the relative
values of metabolites at different times, the rate of uptake or
secretion of a range of metabolites is determined. These rates can
be applied to the model as additional constraints that will restrict
the model predictions to those consistent with the metabolic
dataset (Bordbar et al., 2017). These additional constraints help
to predict different sets of active and inactive intracellular
reactions based on extracellular data. This process may follow
a protocol such as Metabotools. This protocol has been used to
obtain metabolic insights into the metabolic differences between
different leukemic cell lines (Aurich et al., 2015, 2016; von
Bomhard et al., 2016).
Models can also be used to analyze isotope labeling data and
this data can, in turn, contribute better constraints to improve
the model. Cells may be fed on medium containing glucose or
glutamine labeled with heavy isotopes of carbon or nitrogen.
The proportions of various metabolites labeled with these heavy
isotopes in cells that are sampled and analyzed at different time
points after this treatment allows inferences to be made about
the production of the labeled metabolites. Sholmi et al. used this
technique to elucidate the differences in the TCA cycle during
the cell cycle. Further information may be obtained if the cells are
fractionated into different organelles before analysis (Ahn et al.,
2017). For example, the subcellular localization of glutamine
metabolism in cancer has been elucidated using this technique
(Lee et al., 2019).
Using the model building algorithm (MBA) (Jerby et al.,
2010), which generates tissue-specific models, a focused model
for cancer metabolism has been created containing a core set
of reactions known to be common for 60 variant cancer cell
lines. Using this model and the knowledge that uncontrolled cell
growth and altered metabolism are characterizing hallmarks for
cancer cells, it was possible to identify two different types of
drug targets (Hanahan and Weinberg, 2011; Dougherty et al.,
2017). The first target type was growth-supporting genes (found
via in silico gene deletion screens) that resulted in identification
of 52 metabolic drug targets; 8 of these currently correspond to
cancer therapeutics. In addition, a set of genes were identified in
the healthy cell model network that were downregulated in the
cancer model. By inhibiting the genes more highly expressed in
cancer cells, targeting could be achieved (Dougherty et al., 2017).
More specific cancer models have also been produced. For
example, a model has been created for hepatocellular carcinoma
by Agren et al. (2014). They evaluated the presence of proteins in
27 patients and from that reconstructed personalized GEMs for
six. These reconstructions were then used to identify anticancer
drugs by observing the inhibition of reactions around each
metabolite in a network and the subsequent effects on cellular
growth within the models. By conceptualizing drugs as structural
analogs to metabolites, and so capable of interfering with
target enzymes and enzymatic activity, 101 antimetabolites were
predicted as possible drug targets (Agren et al., 2014). Similar
approaches have been applied to breast cancer undergoing
epithelial-to-mesenchymal transition in order to identify targets
to reduce this pro-metastatic process (Halldorsson et al., 2017).
Comparing Models of Cells in Different
Circumstances Can Produce Useful Insights Into
Metabolism
Many constraint-based metabolic analyses have historically relied
upon an objective function, which is defined as a metabolic
objective of a cell; flux through this reaction is either maximized
or minimized to compute the flux state (i.e., pathway usage)
across the entire network. For metabolic states that do not
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have as well-defined objective functions as cancer does (i.e.,
gross cellular growth), algorithms that are able to create tissue-
or cell-specific models without a specific objective function
are needed. An algorithm often used for this purpose is the
metabolic transformation algorithm (MTA) (Yizhak et al., 2013),
an algorithm that uses GEMs to predict genetic perturbations
that are able to shift a diseased metabolic state toward a healthy
one. This algorithm has been used to determine reactions
capable of shifting “old” muscle into “young” (providing potential
targets that can help reducing metabolic shifts related to aging)
and to determine key reactions that, when removed from
a GEM modeling Alzheimer’s disease, resulted in a network
reconstruction more similar to that of a healthy state (Stempler
et al., 2014; Wone et al., 2018).
Obesity has been addressed through the use of the human
metabolic reconstruction by identifying pathways implicated
in the disease process. As with many diseases, pinpointing a
specific genetic or environmental marker as a cause for obesity,
making the determination of progression, and deciding on a
“treatment” a difficult task. Using the HMR and transcriptomic
data from both healthy and obese individuals, a GEM with
the objective function defined as acetyl-CoA production and
formation of lipid droplets was produced. Through this analysis,
two possible drug targets were identified by considering reactions
with significantly changed flux values, and a potential biomarker
for obesity was identified through reporter metabolites, which is
an algorithm allowing the analysis of transcriptomic data in the
light of the metabolic network structure to predict highly affected
metabolites (Bordbar et al., 2011; Väremo et al., 2013; Levian
et al., 2014; Dougherty et al., 2017).
Drug toxicity levels and side effects over both short and
long periods of usage can also be identified in an easier
and more cost-efficient manner using GEMs. It is possible to
make predictions on system-wide perturbations using previously
determined information on how protein structural analysis can
be used to determine off-target binding of drugs, in combination
with metabolic networks, as was done by Chang et al. (2010).
Metabolic Models Can Be Used to Uncover Changes
Over Time
Biological systems often change dynamically over time.
Analyzing how these changes occur can be challenging but
is being addressed through the integration of time-course
experimental data. One approach, dynamic flux balance analysis
(dFBA) {ref 10.1016/j.celrep.2017.07.04}, integrates time-course
measurements of the major inputs and outputs of the system
to provide more accurate flux predictions. dFBA provides a
continuous prediction based on these changing inputs and
outputs (e.g., end products of pathways). This method has been
applied to murine embryonic stem cells and revealed changes to
mitochondrial metabolism and one carbon metabolism during
priming (Shen et al., 2019). more recently, time-course -omic
measurements have been integrated with metabolic models.
One such method, unsteady-state flux balance analysis (uFBA),
integrates absolutely quantified time-course metabolomic data
to model cellular dynamics. uFBA was used to explore how
temporal dynamics impact the cellular metabolism of stored red
blood cells, which led to the proposal of better storage solutions
that could potentially increase the storage time and quality of
this key medical product. Such methods may be applied to other
cell types and phenotypes in the future where dynamics play a
key role. In MSCs, for example, key metabolic shifts that occur
during trilineage differentiation may be examined and compared
as a function of time.
A Metabolic Model of MSCs Has Already Predicted
Better Ways to Expand MSC Cultures
A GEM of MSCs, iMSC1255, was recently created to improve
understanding of the function of MSC metabolism. This model
is based upon publicly available transcriptomic data sets from
proliferating, early passage bone marrow MSCs. The data was
used with the mCADRE algorithm to generate a tissue-specific
version of the global human model Recon1, which was then
manually curated by comparison to proteomic data and the
literature to ensure that all desirable reactions were included
to account for known MSC metabolic functions (Wang et al.,
2012). Further metabolic constraints were added based on the
composition of the commonly used medium alpha MEM, which
meant that the modeled cells were able to take up metabolites
known to be available in alpha MEM. This model was compared
to previous models created with the same algorithm for adipose,
bone marrow, and blood (using tissue-based, rather than cell-
based, models). These previous models were shown to be
less specific than iMSC1255. iMSC1255 was also shown to be
able to produce amino acid uptake and secretion and growth
rate predictions consistent with data available in the literature
(Fouladiha et al., 2015).
iMSC1255 has subsequently been used to computationally
predict metabolic interventions to optimize proliferation
and chondrogenic differentiation of MSCs. By analyzing
the maximum growth rate predicted FBA with and without
allowing the uptake of a range of nutrients, it was proposed
that supplementing the MSC medium with the phospholipids
phosphoethanolamine and phosphoserine would improve
proliferation. This was confirmed experimentally (Fouladiha
et al., 2018). This paper also describes how MTA was used along
with transcriptomic data from chondrocytes to determine likely
metabolic changes during chondrocyte differentiation. This
analysis suggested that mitochondrial transport reactions are
key to chondrocyte differentiation, a finding that has yet to be
experimentally confirmed. Further, the authors also examined
the effects of hypoxia on proliferating MSCs by assessing the
range of possible metabolic activities when the models use
different levels of oxygen and glucose availability. The predicted
metabolic changes to lactate and glucose uptake and secretion,
G6P isomerase, and pyruvate transport were generally correct,
with the exception of superoxide dismutase, according to the
literature (Fouladiha et al., 2018). This study showed that a
model of MSC metabolism can provide useful insights into their
proliferation under different circumstances. This will allow the
optimization of MSC growth that may be useful for large scale
production of MSC-based therapeutics. Follow-up work has
begun to examine the potential of GEMs to predict changes
necessary for successful differentiation (Fouladiha et al., 2018).
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 16 March 2020 | Volume 8 | Article 239
fbioe-08-00239 March 28, 2020 Time: 19:28 # 17
Sigmarsdóttir et al. Metabolic Models in Regenerative Medicine
By expanding upon such techniques, including by using models
constrained with metabolic data from differentiating cells, this
can be built upon.
LOOKING AHEAD
Since 2007, when the very first global GEM for humans
was reconstructed (Duarte et al., 2007), researchers have been
exploring the clinical application possibilities of GEMs. Some of
the possible ways GEMs can be of use in furthering the clinical
application of cell-based medicine include: (1) trials with in silico
metabolic engineering (gene knock-outs and knock-ins); (2)
identifying biomarkers of diseases; (3) predicting drug targets and
therapeutic windows; and (4) optimization of cellular functions
without the cost of wet lab experimentation. Some success has
already been reported, as mentioned in section “Current State-
of-the-Art Applications.”
Manipulation of the Metabolic State
Building on the various uses of existing cell- or tissue-specific
human GEMs and the most up-to-date version of the human
reconstruction (Brunk et al., 2018), the potential use of GEMs to
explore methods to maintain or manipulate a desired metabolic
state for hMSCs (in order to provide a specific function or
desired effect) has been the subject of work done by Fouladiha
et al. They demonstrated the potential of GEMs to gain insight
into how MSCs may be manipulated by means of nutrient
supplementation (Fouladiha et al., 2018). By adding nutrients
into the growth medium or manipulating oxygen concentration
in silico, the number of experiments needed to optimize growth
conditions may be reduced. This may be an interesting avenue to
explore for each cell type and cell state, since different responses
may be observed. Such testing is more feasible to explore in silico
than in vitro. Even though time and money will have to be
spent on reconstruction of the GEMs themselves, the savings
in experimental time and material costs afforded by the use
of validated reconstructions will likely outweigh these costs.
Promising in silico outcomes can then be taken further, being
validated or explored in vitro and later in vivo. Positive results
would further validate the models and perhaps further that
particular avenue of cell-based medicine or that particular use of
the cells in regenerative medicine.
Exploration of Metabolic Differences
One potential use for GEMs would be to explore the different
metabolic capacities of hMSCs from different sources. There have
been some reports, albeit limited, explaining possible differences
in the proliferative, differentiation, and immunomodulatory
abilities of hMSCs isolated from various tissues (Liu et al.,
2007; Hass et al., 2011; Secunda et al., 2015; Tachida et al.,
2015). As hMSCs are isolated from disparate microenvironments,
some with large differences in their surroundings, their optimal
survival conditions and, possibly, utilization potential may differ.
For example, by comparing models created using transcriptomics
data from a study of MSCs from various sources such as
ArrayExpress (EMBL-EBI, 2014; Athar et al., 2019) and then
subjecting them to comparative flux analysis, different metabolic
patterns may be discovered and linked to previously reported
functional differences, such as the ability to form hematopoietic
cells. Results could be verified or supplemented with data from
independent proteomics experiments such as can be found via
PRIDE Archive (Billing et al., 2016).
The creation and study of GEMs of MSCs undergoing
each of the three classical differentiation (adipo-, osteo- and
chondrogenic) could be approached in various ways. uFBA could
be used as a framework to examine MSC metabolomics data
collected at different timepoints during each of the differentiation
lineages (Bordbar et al., 2017). The study of other stem cell
types over time has already provided useful insights into
differentiation from a transcriptional viewpoint. uFBA would
allow a better understanding of the metabolic changes to be
reached (Bordbar et al., 2017).
Experimental Cost Reduction via in silico
Result Prediction
As expansion and differentiation of MSCs is a time-consuming
and potentially expensive process, it would be desirable to be
able to predict in advance the success of cells from a particular
donor. For example, a signature pattern of gene features could
be tested before donation. To this end, a model of successful and
unsuccessful cells created with Recon3D could be used to analyze
the genes relevant to an ideally differentiated model in silico
(Strober et al., 2019). Single and combined gene deletion to find
genes essential to each form of differentiation would be useful
as a secondary way of finding a genetic signature for successful
differentiation. This process could provide a means of reducing
the necessary number of in vitro analyses.
It would also be desirable to confirm adequate differentiation
by measuring a few metabolites before attempting implantation.
The reporter metabolites algorithm (Çakır, 2015; Schultz and
Qutub, 2016) applied to a model of well- differentiated MSCs
would determine exometabolomic biomarkers that are indicative
of successful levels of differentiation.
Multi-Cell Models
Community models or multi-cell models are another avenue to
be explored as a potential use for GEMs to enhance the use
of hMSCs in regenerative medicine. These models can provide
insight into the metabolic functions of possible interacting
organisms or the various cell types residing within the same
organism (Levy and Borenstein, 2013; Dougherty et al., 2017).
Given that hMSCs are intended to be integrated into a host
system for clinical application (Han et al., 2012; Levy and
Borenstein, 2013; Burke et al., 2016; Archambault et al., 2017;
Goldberg et al., 2017; Moreira et al., 2017; Cunningham et al.,
2018; Hu et al., 2018; Ibraheim et al., 2018; Solarte et al., 2018),
this could provide useful insights.
Recently, more attention has been given to the hMSC
secretome and its possible therapeutic effect; this might be well
explored through the use of multi-cellular GEMs. The secretome
of hMSCs might be manipulated via some of the previously
mentioned methods, and the effect of composition changes on
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the targeted organism, cell, and/or environment observed. This
could help to find novel directions in which to expand the use of
hMSCs in regenerative medicine.
Age Related Exploration
Yet another aspect that could more easily be explored through
the use of GEMs covering hMSCs is the effect of donor
age. This is not the same as cell senescence, but effects
due to age have been observed in hMSCs lines through
in vitro experiments (Choudhery et al., 2014; Narbonne, 2018).
This appears in the way that cells are able to perform
with regard to proliferation speed, differentiation ability, and
immunomodulation. There have been numerous attempts to
return functionality to stem cells from aged donors, with some
degree of success (Neves et al., 2017). However, with the
application of GEMs, the significant changes and the reasons
behind them may be more systematically documented and
attempts to return function performed in a more cost-effective
and time-saving manner.
Overall, the use of GEMs to further the use of hMSCs in
regenerative medicine is increasing, but, as of yet, is a relatively
unexplored avenue that holds a lot of promise. We anticipate
that in silico metabolic modeling will help to elucidate the
differentiation process of hMSCs, ultimately providing crucial
insights into novel therapies in the field of regenerative medicine.
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